吉非替尼联合吉西他滨和顺铂治疗晚期非小细胞肺癌的疗效

打开文本图片集

摘 要 目的：观察吉非替尼联合吉西他滨和顺铂治疗晚期非小细胞肺癌的临床效果。方法：将98例晚期非小细胞肺癌患者随机分成对照组和研究组，各49例。对照组实施吉西他滨联合顺铂治疗，研究组在对照组基础上加用吉非替尼，对比两组临床疗效。结果：治疗后，研究组治疗总有效率，CD3+、CD4+水平和CD4+/CD8+比值均高于对照组；CD8+水平和不良反应发生率均低于对照组（P

关键词 吉非替尼 吉西他滨 顺铂 晚期非小细胞肺癌 疗效

中图分类号：R979.19； R734.2 文献标志码：A 文章编号：1006-1533（2023）07-0011-03

引用本文 陈辉， 黄武君， 崔明良. 吉非替尼联合吉西他滨和顺铂治疗晚期非小细胞肺癌的疗效[J]. 上海医药， 2023， 44（7）： 11-13.

Efficacy of gefitinib combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer

CHEN Hui， HUANG Wujun， CUI Mingliang

（Department of Oncology， Balihu General Hospital， the First People’s Hospital of Jiujiang City， Jiujiang 332000， China）

ABSTRACT Objective： To observe the clinical effect of gefitinib combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer. Methods： Ninety-eight patients with advanced non-small cell lung cancer were randomly divided into a control group and a study group with 49 cases each. The control group was treated with gemcitabine combined with cisplatin， while the study group was treated with gefitinib besides gemcitabine combined with cisplatin. The clinical efficacy was compared between the two groups. Results： The overall clinical efficacy， the levels of CD3+， CD4+， and CD4+/CD8+ were higher， and the level of CD8+ and the incidence of adverse events were lower in the study group than the control group after the treatment （P

KEY WORDS gefitinib； gemcitabine； cisplatin； advanced non-small cell lung cancer； efficacy

肺癌是一种患病率、致死率较高的恶性肿瘤，其中非小细胞肺癌（non-small cell lung cancer， NSCLC）约占80%[1]。（剩余3404字）